Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306)

Ruth Pettengell, Monika Długosz-Danecka, David Andorsky, David Belada, Pencho Georgiev, Donald Quick, Jack W Singer, Simran B Singh, Athanasios Pallis, Anton Egorov, Gilles Salles, Ruth Pettengell, Monika Długosz-Danecka, David Andorsky, David Belada, Pencho Georgiev, Donald Quick, Jack W Singer, Simran B Singh, Athanasios Pallis, Anton Egorov, Gilles Salles

Abstract

PIX306 was a phase 3, randomised, single-blind, multicentre trial conducted in adult patients with diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) grade 3 who relapsed after ≥1 rituximab-containing regimen and were not eligible for a stem cell transplant. Patients were randomised 1:1 to pixantrone 50 mg/m2 or gemcitabine 1000 mg/m2 on days 1, 8 and 15 of a 28-day cycle, combined with rituximab 375 mg/m2 on day 1, for up to six cycles. Patients were followed for up to 96 weeks. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), complete response (CR) rate, overall response rate (ORR) and safety. Overall, 312 patients were randomised (median age 73·0 years). The study did not meet its primary endpoint. Median PFS [95% confidence interval (CI)] was 7·3 months (5·2-8·4) with pixantrone + rituximab (PIX + R) and 6·3 months (4·4-8·1) with gemcitabine + rituximab [GEM + R; hazard ratio (HR): 0·85; 95% CI 0·64-1·14; P = 0·28]. Median OS was 13·3 (10·1-19·8) months with PIX + R and 19·6 (12·4-31·9) months with GEM + R (HR: 1·13; 95% CI 0·83-1·53). ORR was 61·9% and 43·9% respectively and CR rate 35·5% and 21·7%. The incidence of adverse events, including cardiac events, was not statistically significant different between PIX + R and GEM + R.

Keywords: DLBCL; FL grade 3; gemcitabine; pixantrone; rituximab.

© 2019 British Society for Haematology and John Wiley & Sons Ltd.

References

    1. Belada, D., Georgiev, P., Dakhil, S., Inhorn, L.F., Andorsky, D., Beck, J.T., Quick, D., Pettengell, R., Daly, R., Dean, J.P., Pavlyuk, M., Failloux, N. & Hubel, K. (2016) Pixantrone-rituximab versus gemcitabine-rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma. Future oncology, 12, 1759-1768.
    1. Bierman, P.J. (2007) Natural history of follicular grade 3 non-Hodgkin's lymphoma. Current opinion in oncology, 19, 433-437.
    1. Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Fisher, R.I., Hagenbeek, A., Zucca, E., Rosen, S.T., Stroobants, S., Lister, T.A., Hoppe, R.T., Dreyling, M., Tobinai, K., Vose, J.M., Connors, J.M., Federico, M. & Diehl, V. (2007) Revised response criteria for malignant lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25, 579-586.
    1. Clausen, M.R., Leppa, S., Brown, P.d.N., Goerloev, J.S., Panny, M., Willenbacher, W., Sillesen, I.B., Segel, E., Bentzen, H., Thorsgaard, M., Pulczynski, E.J., Kamper, P., Gormsen, L.C., Mortensen, J., Lauritzsen, G., Relander, T. & d'Amore, F. (2016) The combination of pixantrone, etoposide, bendamustine and in CD20+ tumors, rituximab (PREBEN) shows promising feasibility/efficacy in heavily pre-treated aggressive lymphomas of B- and T-cell phenotype - results of the pre-trial experience leading to a Nordic phase 1/2 study (the PREBEN Trial). Blood, 128, 1782-1782.
    1. European Medicines Agency (2012) Pixurvri: EPAR - Public assessment report, vol. 2018. European Medicines Agency, London.
    1. Farooq, U., Maurer, M.J., Thompson, C.A., Thanarajasingam, G., Inwards, D.J., Micallef, I., Macon, W., Syrbu, S., Lin, T., Lin, Y., Ansell, S.M., Nowakowski, G.S., Habermann, T.M., Cerhan, J.R. & Link, B.K. (2017) Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy. British journal of haematology, 179, 50-60.
    1. Ferlay, J., Steliarova-Foucher, E., Lortet-Tieulent, J., Rosso, S., Coebergh, J.W., Comber, H., Forman, D. & Bray, F. (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. European journal of cancer, 49, 1374-1403.
    1. Gisselbrecht, C. & Van Den Neste, E. (2018) How I manage patients with relapsed/refractory diffuse large B cell lymphoma. British journal of haematology, 182, 633-643.
    1. Hernandez, I., Prasad, V. & Gellad, W.F. (2018) Total costs of chimeric antigen receptor T-cell immunotherapy. JAMA oncology, 4, 994-996.
    1. Institute for Clinical and Economic Review (2018) Chimeric antigen receptor T-cell therapy for B-cell cancers: effectiveness and value. Final evidence report. Vol. 2019. Institute for Clinical and Economic Review, Boston, MA.
    1. Kane, E., Howell, D., Smith, A., Crouch, S., Burton, C., Roman, E. & Patmore, R. (2017) Emergency admission and survival from aggressive non-Hodgkin lymphoma: a report from the UK's population-based Haematological Malignancy Research Network. European journal of cancer, 78, 53-60.
    1. Kuruvilla, J., Keating, A. & Crump, M. (2011) How I treat relapsed and refractory Hodgkin lymphoma. Blood, 117, 4208-4217.
    1. Lee, L., Wang, L. & Crump, M. (2011) Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 22, 1392-1403.
    1. Mangal, N., Salem, A.H., Li, M., Menon, R. & Freise, K.J. (2018) Relationship between response rates and median progression-free survival in non-Hodgkin's lymphoma: A meta-analysis of published clinical trials. Hematological oncology, 36, 37-43.
    1. National Comprehensive Cancer Network (2018) NCCN clinical practice guidelines in oncology: B-cell lymphomas. Version 4.2018. Vol. 2018.
    1. Neelapu, S.S., Locke, F.L., Bartlett, N.L., Lekakis, L.J., Miklos, D.B., Jacobson, C.A., Braunschweig, I., Oluwole, O.O., Siddiqi, T., Lin, Y., Timmerman, J.M., Stiff, P.J., Friedberg, J.W., Flinn, I.W., Goy, A., Hill, B.T., Smith, M.R., Deol, A., Farooq, U., McSweeney, P., Munoz, J., Avivi, I., Castro, J.E., Westin, J.R., Chavez, J.C., Ghobadi, A., Komanduri, K.V., Levy, R., Jacobsen, E.D., Witzig, T.E., Reagan, P., Bot, A., Rossi, J., Navale, L., Jiang, Y., Aycock, J., Elias, M., Chang, D., Wiezorek, J. & Go, W.Y. (2017) Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. The New England journal of medicine, 377, 2531-2544.
    1. Neelapu, S.S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F.L., Komanduri, K.V., Lin, Y., Jain, N., Daver, N., Westin, J., Gulbis, A.M., Loghin, M.E., de Groot, J.F., Adkins, S., Davis, S.E., Rezvani, K., Hwu, P. & Shpall, E.J. (2018) Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nature reviews. Clinical oncology, 15, 47-62.
    1. Pettengell, R., Coiffier, B., Narayanan, G., de Mendoza, F.H., Digumarti, R., Gomez, H., Zinzani, P.L., Schiller, G., Rizzieri, D., Boland, G., Cernohous, P., Wang, L., Kuepfer, C., Gorbatchevsky, I. & Singer, J.W. (2012) Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. The Lancet Oncology, 13, 696-706.
    1. Pettengell, R., Sebban, C., Zinzani, P.L., Derigs, H.G., Kravchenko, S., Singer, J.W., Theocharous, P., Wang, L., Pavlyuk, M., Makhloufi, K.M. & Coiffier, B. (2016) Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: post-hoc analyses from a phase III trial. British journal of haematology, 174, 692-699.
    1. Salles, G.A., Pettengell, R., Cordoba, R., Dlugosz-Danecka, M., Jurczak, W. & Tilly, H. (2019) Treatment of aggressive B-cell non-Hodgkin lymphoma beyond frontline therapy in patients not eligible for stem cell transplantation: a structured review. Leukemia & lymphoma, 1-16.
    1. Schuster, S.J., Svoboda, J., Chong, E.A., Nasta, S.D., Mato, A.R., Anak, O., Brogdon, J.L., Pruteanu-Malinici, I., Bhoj, V., Landsburg, D., Wasik, M., Levine, B.L., Lacey, S.F., Melenhorst, J.J., Porter, D.L. & June, C.H. (2017) Chimeric antigen receptor T cells in refractory B-cell lymphomas. The New England journal of medicine, 377, 2545-2554.
    1. SEER (2018) Cancer stat facts: non-Hodgkin lymphoma. In: Surveillance, Epidemiology, and End Results Program, Vol. 15 June 2018. National Cancer Institute, Bethesda, MD, USA.
    1. Swerdlow, S.H., Campo, E. & Harris, N.L. (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon.
    1. Teachey, D.T., Bishop, M.R., Maloney, D.G. & Grupp, S.A. (2018) Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nature reviews. Clinical oncology, 15, 218.
    1. Tilly, H., Gomes da Silva, M., Vitolo, U., Jack, A., Meignan, M., Lopez-Guillermo, A., Walewski, J., Andre, M., Johnson, P.W., Pfreundschuh, M. & Ladetto, M. (2015) Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 26, v116-125.
    1. Zhu, R., Lu, D., Chu, Y.W., Chai, A., Green, M., Zhang, N. & Jin, J.Y. (2017) Assessment of correlation between early and late efficacy endpoints to identify potential surrogacy relationships in non-Hodgkin lymphoma: a literature-based meta-analysis of 108 phase II and phase III studies. The AAPS journal, 19, 669-681.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren